Bioventus INC 10-Q quarterly reports

Bioventus Inc. announced robust financial results for the second quarter of 2026, showcasing significant revenue increases and improved net income, driven by strong performance in its U.S. Pain Treatments segment.

Bioventus Inc. announced its first quarter 2026 financial results, showing a significant increase in net sales and a return to profitability.

Bioventus Inc. reported a significant return to profitability in Q3 2025, driven by reduced expenses and strategic product launches, despite a slight dip in net sales.

Bioventus Inc. reported a significant return to net income in Q2 2025, driven by strategic divestitures and new product clearances, despite a slight decline in overall net sales.

Bioventus Inc.'s Q1 2025 net sales decreased by 4.3% year-over-year, primarily due to the divestiture of its Advanced Rehabilitation Business.

Bioventus Inc. announced its third quarter 2024 financial results, including a net loss, and the planned divestiture of its Advanced Rehabilitation Business.

Bioventus Inc. announced its second quarter 2024 results, highlighting revenue growth alongside a significant impairment charge related to a planned divestiture and costs associated with a shareholder litigation settlement.

Bioventus Inc. saw a revenue increase of 8.7% in the first quarter of 2024, despite a net loss from continuing operations.